-
Chongqing Lummy Pharmaceutical’s Generic Ramosetron Passes GQCE in China
•
China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of Astellas Pharma’s Nasea (ramosetron) has become the first to pass the generic quality and efficacy consistency evaluation (GQCE) process in China. The product received marketing approval in China in May 2005. Ramosetron’s Indications and Market…
-
Chongqing Lummy Pharmaceutical’s Subsidiary Receives NMPA Approval for CUD002 mRNA Vaccine
•
Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006), through its subsidiary Sichuan Cunde Therapeutics Co., Ltd, has received clinical trial approval from the National Medical Products Administration (NMPA) for the CUD002 injection. This mRNA-edited DC (dendritic cell) tumor therapeutic vaccine product is based on patient tumor neoantigens, marking a significant step…
-
Hainan Shuangcheng to Transfer Triptorelin Assets to Chongqing Lummy for USD 4.7M
•
Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) will transfer all tangible and intangible assets and rights related to its triptorelin product in designated territories to Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) for RMB 32 million (USD 4.7 million). The deal includes intellectual property, production technology, and marketing approvals for…
-
Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation
•
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership with Wuhan YZY Biopharma Co., Ltd, originally signed in September 2020. The deal granted Lummy exclusive priority sales rights to YZY Bio’s Y400, a bispecific antibody (BsAb) targeting VEGFA and ANG2, in Greater China. YZY…
